careers investors newsroom suppliers alumni login worldwide ELI LILLY AND COMPANY home about responsibility products r & d KEY ISSUES HERITAGE KEY FACTS GLOBAL BUSINESS AREAS BOARD OF DIRECTORS EXECUTIVE COMMITTEE CORPORATE GOVERNANCE BUSINESS PRACTICES KEY ISSUES Personalized Medicine Research & Development Intellectual Property Follow-On Biologics U.S. Patent Protection Patient Education Ethical Interactions Industry Transparency Medicare Part D Access & Affordability Supply Chain Health Technology Assessment Comparative Effectiveness Research Value-Based Pricing Price Controls Role Of Generics Healthcare Reform U.S. Tax Reform Trade Agreements Non-Communicable Diseases DIVERSITY LILLY FOUNDATION LILLY GRANT OFFICE Lilly produces medicines to meet patients' healthcare needs. We believe that it is critical for patients to have access to our products, which save and improve lives. Therefore, Lilly is committed to participating in the political process as a responsible corporate citizen to help inform the debates regarding health care and pharmaceutical innovation globally. Lilly considers a variety of factors and stakeholder input to determine which issues are most relevant for engagement. These factors include patient needs, conversations and interviews with stakeholders, investor queries and feedback, business strategy, public policy dialogue and legislative debate, and employee interests. Intellectual Property Because future biopharmaceutical innovation is dependent upon it, Lilly supports strong and effective protection of intellectual property rights to help ensure inventors have an exclusive, yet limited, period of time to develop and market their products. Access & Affordability Because of the many economic, governmental and social factors that affect accessibility to medicines, Lilly focuses on areas where we know we can make a difference. We partner to develop solutions for access to medicines in developing countries. Value Based Pricing Lilly believes that our medicine prices reflect their value. In pricing our medicines, we consider the value provided to patients, providers, payers and the industry. Comparative Effectiveness Research Lilly supports comparative effectiveness research when used to help inform individual treatment decisions made by physicians and patients, to explore opportunities for broader improvements in healthcare systems, and to address public health challenges. Medicare Part D The successful prescription drug benefit in the U.S. Medicare program is an example that a competitive private market is key to providing the best care for patients. Lilly believes the competitive value of Part D must be maintained. Healthcare Reform Lilly believes that effective healthcare policy is contingent on a balance between access, quality and cost. We support healthcare reform packages that extend healthcare access to those who currently lack it, while preserving or improving access for those who have it today. Copyright © 2021 Eli Lilly and Company. All rights reserved. terms of use privacy sitemap contact